275 related articles for article (PubMed ID: 11341130)
1. Lessons from cisapride.
CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
[No Abstract] [Full Text] [Related]
2. Cisapride and patient information leaflets.
Sukkari SR; Sasich LD
CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
[No Abstract] [Full Text] [Related]
3. The impact of wording in "Dear doctor" letters and in black box labels.
Weatherby LB; Nordstrom BL; Fife D; Walker AM
Clin Pharmacol Ther; 2002 Dec; 72(6):735-42. PubMed ID: 12496755
[TBL] [Abstract][Full Text] [Related]
4. Cisapride fallout? Canada to gain access to largest adverse-event database.
Sibbald B
CMAJ; 2002 Oct; 167(7):790. PubMed ID: 12389847
[No Abstract] [Full Text] [Related]
5. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
[TBL] [Abstract][Full Text] [Related]
6. Cisapride: the problem of the heart.
Premji SS; Paes B
Neonatal Netw; 1999 Oct; 18(7):21-5. PubMed ID: 10808885
[TBL] [Abstract][Full Text] [Related]
7. Patient package inserts: the proper prescription?
Rowe HM
Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
[No Abstract] [Full Text] [Related]
8. A quantitative analysis of adverse events and "overwarning" in drug labeling.
Duke J; Friedlin J; Ryan P
Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
[No Abstract] [Full Text] [Related]
9. Flight 483 now boarding.
Czap A
Altern Med Rev; 2010 Sep; 15(3):183-5. PubMed ID: 21155619
[No Abstract] [Full Text] [Related]
10. Drug recalls underscore safety concerns.
Greene HL
Health News; 2000 May; 6(5):4. PubMed ID: 10851966
[No Abstract] [Full Text] [Related]
11. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
12. Update from the Canadian Dyspepsia Working Group.
Veldhuyzen van Zanten SJ; Flook N; Chiba N; Armstrong D; Barkun A; Bradette M; Thomson A; Bursey F; Blackshaw P; Frail D; Sinclair P
CMAJ; 2000 Sep; 163(6):696. PubMed ID: 11022579
[No Abstract] [Full Text] [Related]
13. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
Cheng C; Guglielmo BJ
Arch Intern Med; 2011 May; 171(10):946-7. PubMed ID: 21606102
[No Abstract] [Full Text] [Related]
14. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
15. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Jacobson JD; Feigal D
Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
[No Abstract] [Full Text] [Related]
16. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
Ehrenpreis ED; Ciociola AA; Kulkarni PM;
Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
[No Abstract] [Full Text] [Related]
17. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
18. Cisapride class-action suit approved.
Comeau P
CMAJ; 2007 Feb; 176(5):615. PubMed ID: 17325320
[No Abstract] [Full Text] [Related]
19. The drug safety system conundrum.
Tiedt TN
Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
[No Abstract] [Full Text] [Related]
20. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
